Morgan Stanley analyst Cecilia Furlong lowered the firm’s price target on Edwards Lifesciences to $92 from $98 and keeps an Overweight rating on the shares following the company’s annual investor day. Edwards’ initial 2023 outlook was about in-line with estimates and appears "realistic," according to Lewis, who said the reiteration of the 2028 long-range outlook frames "a path to recovery and growth," but adds that "signs of recovery are still needed to instill confidence."
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on EW:
- Edwards Lifesciences to host investor meeting
- Edwards Lifesciences backs FY22 adjusted EPS view $2.40-$2.50, consensus $2.46
- Edwards Lifesciences sees FY23 adjusted EPS $2.45-$2.60, consensus $2.53
- EDWARDS LIFESCIENCES OUTLINES GROWTH STRATEGY AT ANNUAL INVESTOR CONFERENCE
- Edwards Lifesciences CEO Michael Mussallem to retire, Bernard Zovighian succeeds